Navigation Links
New genomic markers associated with risk of heart disease and early heart attack
Date:2/18/2009

Five short reports published simultaneously by the journal Nature Genetics have for the first time identified clusters of genetic markers associated with heart attack and coronary heart disease. In one of the reports, from the largest ever study of its kind, the Myocardial Infarction Genetics Consortium identified nine precise genes associated with an increased risk of infarction (MI), three of them newly discovered; the investigators said that these nine gene variants "identify 20% of the population at 2.25-fold increased risk for MI".

This study set out to find "single letter" differences in gene sequences (known as single nucleotide polymorphisms, SNPs) in 26,000 individuals in ten countries in order to explain why the pattern of early onset heart attack is often clustered in families. Using recently developed techniques for comparing an individual's gene sequences with reference sequences, the researchers found significant associations with risk of early heart attack for common SNPs in nine genetic regions.

One of the investigators, Dr Sekar Kathiresan from the Consortium, said: "Since we already have effective ways to reduce heart-attack risk, individuals at higher genetic risk may benefit from earlier intervention, something that needs to be tested in future studies."

Other studies reported in the journal included one from the Universite Pierre et Marie Curie in Paris which newly identified a new gene cluster (of three genes) as a possible susceptibility site for coronary artery disease. This study, unlike the first, compared individual and reference groups of SNPs (known as haplotypes).

Adding the studies together, the results suggest the identification of several new gene sites (loci) which appear to affect the risk of coronary heart disease and early heart attack. So far, the added risk from any abnormality in these gene sequences seems small, but the genomic association seems clear. Furthermore, there seems no specific theme to the SNPs involved, suggesting that, while the expression (phenotype) of heart disease and infarction may be consistent, the pathways of risk may be multiple at the genetic level.

Speaking on behalf of the European Society of Cardiology, Professor Thomas Lscher from the University of Zurich in Switzerland agreed that risk stratification via genetic pathways in coronary heart disease is an important future approach, but warned that these latest results reported in Nature Genetics were from case-control and not prospective studies. He said: "The next stage is to confirm the results in a prospective cohort to find out if they really do provide the same sort of prognostic information we already have from the classical risk factors."

Professor Lscher added that there is also a need to discover what the SNPs and gene clusters are doing biologically. "We have to find out what's going on at the cellular level as well," he said. "Several of the SNPs have been linked to cholesterol metabolism in the liver, but there are some new ones here associated with coronary artery disease and atherosclerosis.

"This is important work but we need further evidence with statistical power and biological plausibility."


'/>"/>

Contact: ESC Press Office
press@escardio.org
33-049-294-8627
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. NeoGenomics to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
2. Van Andel Research Institute of Michigan and Translational Genomics Research Institute of Arizona Undertake Unprecedented Alliance to Promote Science and Health
3. New genomic test can personalize breast cancer treatment
4. ANA and ISONG Co-Publish Genetics and Ethics in Health Care: New Questions in the Age of Genomic Health
5. Genomic Health to Announce Fourth Quarter and Year-End 2008 Financial Results and Host Conference Call on Tuesday, February 3, 2009
6. AutoGenomics CYP 2C19 Test Used in Study to Personalize Clopidogrel (Plavix) Dosing in Patients
7. Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize DNA Methylation Cancer Tests
8. Genomic Health Announces Management Changes and New Responsibilities
9. Nutrigenomics - Developing Personalized Diets for Disease Prevention - Is the Focus of a Special Issue of OMICS
10. Genomic Health Announces Study Establishing the Utility of Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated with Aromatase Inhibitors
11. Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... in state legislatures and Congress to protect parental rights and civil liberties, and ... safety in America. , The demonstration coincides with a press conference taking place ...
(Date:3/28/2017)... ... ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts of the ... Wentz talked about journey and research recently on a blog and discussed some major ... solution to deal with thyroid disease. , Dr. Wentz completed her graduation from ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... services, is proud to announce it has joined the National Association for Home ... interests of chronically ill, disabled, and dying Americans of all ages and the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, ... the launch of a free, public-facing tool for analyzing the costs of various ... to provide comparative information to patients, providers, insurers and pharmaceutical companies about the ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... that the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control ... , The program, developed in association with efforts by the American College of ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Taiwan , March 28, 2017  Medeon ... medical device company, is pleased to announce that ... A investment of Panther Orthopedics, Inc., a ... innovative dynamic fixation solutions for orthopedic extremity applications.  ... continues to expand rapidly, primarily due to procedure ...
(Date:3/28/2017)... , March 28, 2017  Rosen Law Firm, a ... a class action lawsuit on behalf of purchasers of ... ) pursuant and/or traceable to Kitov,s initial public offering ... on the open market from November 20, 2015 through ... The lawsuit seeks to recover damages for Kitov investors ...
(Date:3/28/2017)... , March 28, 2017 ... Pharmaceutical Marketing Strategies: Digital as a Key Component ... the changing pharmaceutical marketing landscape in the digital ... new technologies to provide medical advancements, it has ... marketing efforts, mostly relying on traditional channels and ...
Breaking Medicine Technology: